Snehal Patel Buys 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were acquired at an average cost of $11.97 per share, for a total transaction of $23,940.00. Following the completion of the acquisition, the chief executive officer now owns 5,543,702 shares of the company’s stock, valued at approximately $66,358,112.94. This trade represents a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Snehal Patel also recently made the following trade(s):

• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Trading Up 9.7 %

NASDAQ GLSI opened at $12.88 on Monday. Greenwich LifeSciences, Inc. has a 12 month low of $8.00 and a 12 month high of $21.44. The stock’s 50 day moving average is $13.20 and its 200 day moving average is $14.17. The stock has a market cap of $169.37 million, a PE ratio of -16.10 and a beta of 1.61.

Hedge Funds Weigh In On Greenwich LifeSciences

Several institutional investors have recently bought and sold shares of the stock. State Street Corp boosted its holdings in shares of Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares in the last quarter. Barclays PLC lifted its position in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after buying an additional 6,538 shares in the last quarter. Rhumbline Advisers bought a new position in Greenwich LifeSciences during the second quarter valued at approximately $117,000. Finally, Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences during the 2nd quarter valued at approximately $264,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.